Leveraging Point-of-Care Diagnostic Testing inside controlled-interconnected ‘Chain-Of-Custody’ Processes.
We are a U.S-based early-stage In Vitro Diagnostics Company on the front end of the fight to combat the ravaging effects of the coronavirus. AG technology will be essential in putting Americans back to work, providing post-pandemic COVID-19 antibody testing solutions to mitigate future outbreaks, and get Americans back to work.
Managing Broad Screening With Over 100 Million+ POC Tests
Leveraging The Growing Understanding of IgG/IgM Antibody Expression and Timing To Determine Primary and Secondary Infection and/or Post- Infection Immunity.
Our POCT Rapid Serology Tests deliver Fast, Scalable, Ease of Use Screening. The tests are easy to understand, easy to run and easy to interpret. Through aggressive population risk stratification of tested and managed individuals, our Antibody Test Kits and Microfluidic Systems deliver calibrated technologies for caregiver safety while providing accurate diagnostics to prevent early-stage failures in disease detection.